The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Neha Manpuria - BofA Global Research - Analyst
: Thank you so much Saurabh. Hi, Peter. Thanks for the opening remarks. A couple of questions. First, I missed your comment on aflibercept. The
line wasn't very clear at my end. If you could just tell us the next steps that Biocon is looking at in terms of aflibercept? And could this still be an
opportunity for us, given our first to filing status in the product?
Question: Neha Manpuria - BofA Global Research - Analyst
: Understood. Thank you so much. My second question is on the BBL business. We have seen traction in terms of revenue quarter-on-quarter. You
did seem to indicate a lot of contract wins across products. So, is it fair to assume, even though there is still uncertainty on the approval timeline
for aspart and beva, what should be the traction of the biosimilar revenue? That's number one. And second, when will that start reflecting in terms
of margins? Because we have this one-off costs for a while now. When do we start seeing that one-off cost getting sort of annualized and seeing
a clean number in BBL going forward?
Question: Neha Manpuria - BofA Global Research - Analyst
: And when do we expect these new approvals, Shreehas? Would it be this second half? Or FY25? FY26? I mean, what's your sense on when we
eventually see this approval given the long wait already?
Question: Neha Manpuria - BofA Global Research - Analyst
: Understood. And sorry, I'm going to squeeze in one more. If I look at the BBL net debt-to-EBITDA, we're tracking over 4 times net debt to EBITDA.
What's the sense of the net debt deduction part that we have for BBL? And what's our comfort level, let's say, 12 months from now?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 09, 2024 / 3:30AM, BION.NS - Q3 2024 Biocon Ltd Earnings Call
Question: Neha Manpuria - BofA Global Research - Analyst
: Understood. Thank you so much, Peter.
| 
